Myeloma Research Publications

Research Publications

Explore Selected Research Publications

We’ve organized a compilation of selected peer-reviewed scientific articles associated with MMRF research projects. Each publication includes citation details — such as title, author, journal, and abstract — which can be explored via keyword search or MMRF project name. The PubMed and DOI link is also provided for each publication, where further details surrounding each study may be accessed.

Search posts

Filter by category

CoMMpass Nature Genetics 2024

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Skerget S, et al.

DOI: 10.1038/s41588-024-01853-0

PMID: 39160255

Multiple myeloma is a treatable, but currently incurable, hematological malignancy of plasma cells characterized by diverse and complex tumor genetics for which precision medicine approaches to treatment are lacking. Read More >

CoMMpass Blood Advances 2024

Dual role of signaling pathways in myeloma requires cell type-specific targeting of ligand-receptor interactions

Hernandez-Lopez P, et al.

DOI: 10.1182/bloodadvances.2023011463

PMID: 38603572

Although the immune microenvironment has been extensively studied in patients with myeloma, its composition is currently not used as prognostic markers in clinical routine. We hypothesized that the outcome of immune signaling pathway engagement can be highly variable, depending on which 2 cellular populations participate in this interaction. Read More >

Clinical Trials Nature Cancer 2024

Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial

Richard, S., et al.

DOI: 10.1038/s43018-024-00818-w

PMID: 39187595

Persons with myeloma were randomized to receive an anti-TIGIT (T cell immunoreceptor) or anti-LAG3 (lymphocyte activation gene) antibody followed by combination with pomalidomide and dexamethasone (NCT04150965). Primary and secondary endpoints were safety and efficacy, respectively. Therapy was well tolerated without dose-limiting toxicity. Read More >

CoMMpass Nature Communications 2022

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

Vo JN, et al.

DOI: 10.1038/s41467-022-31430-0

PMID: 35768438

Multiple myeloma is the second most common hematological malignancy. Despite significant advances in treatment, relapse is common and carries a poor prognosis. Thus, it is critical to elucidate the genetic factors contributing to disease progression and drug resistance. Here, we carry out integrative clinical sequencing of 511 relapsed, refractory multiple myeloma (RRMM) patients to define the disease's molecular alterations landscape. Read More >

CoMMpass Blood Cancer Discovery 2022

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Davies FE, et al.

DOI: 10.1158/2643-3230.BCD-21-0205

PMID: 35653112

The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. Read More >

CoMMpass Cell Reports 2021

Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins

Shirasaki R, et al.

DOI: 10.1016/j.celrep.2020.108532

PMID: 33406420

Heterobifunctional proteolysis-targeting chimeric compounds leverage the activity of E3 ligases to induce degradation of target oncoproteins and exhibit potent preclinical antitumor activity. To dissect the mechanisms regulating tumor cell sensitivity to different classes of pharmacological "degraders" of oncoproteins, we performed genome-scale CRISPR-Cas9-based gene editing studies. Read More >

CoMMpass Clinical Cancer Research 2020

Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing

D'Agostino M, et al.

DOI: 10.1158/1078-0432.CCR-20-0951

PMID: 32616499

Purpose: Duration of first remission is important for the survival of patients with multiple myeloma. Experimental design: From the CoMMpass study (NCT01454297), 926 patients with newly diagnosed multiple myeloma, characterized by next-generation sequencing, were analyzed to evaluate those who experienced early progressive disease. Read More >

CoMMpass Leukemia 2020

Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease

Mason MJ, et al.

DOI: 10.1038/s41375-020-0742-z

PMID: 32060406

While the past decade has seen meaningful improvements in clinical outcomes for multiple myeloma patients, a subset of patients does not benefit from current therapeutics for unclear reasons. Many gene expression-based models of risk have been developed, but each model uses a different combination of genes and often involves assaying many genes making them difficult to implement. Read More >

CoMMpass Nature Communications 2019

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

Barwick BG, et al.

DOI: 10.1038/s41467-019-09555-6

PMID: 31015454

Multiple myeloma is a malignancy of antibody-secreting plasma cells. Most patients benefit from current therapies, however, 20% of patients relapse or die within two years and are deemed high risk. Here we analyze structural variants from 795 newly-diagnosed patients as part of the CoMMpass study. Read More >

CoMMpass Blood 2018

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Walker BA, et al.

DOI: 10.1182/blood-2018-03-840132

PMID: 29884741

Understanding the profile of oncogene and tumor suppressor gene mutations with their interactions and impact on the prognosis of multiple myeloma (MM) can improve the definition of disease subsets and identify pathways important in disease pathobiology. Read More >

CoMMpass PLOS Genetics 2017

Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases

Manojlovic Z, et al.

DOI: 10.1371/journal.pgen.1007087

PMID: 29166413

Multiple Myeloma (MM) is a plasma cell malignancy with significantly greater incidence and mortality rates among African Americans (AA) compared to Caucasians (CA). The overall goal of this study is to elucidate differences in molecular alterations in MM as a function of self-reported race and genetic ancestry. Read More >

CoMMpass Clin. Lymphoma, Myeloma & Leuk. 2017

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma

van Beers EH, et al.

DOI: 10.1016/j.clml.2017.06.020

PMID: 28735890

High risk and low risk multiple myeloma patients follow a very different clinical course as reflected in their PFS and OS. To be clinically useful, methodologies used to identify high and low risk disease must be validated in representative independent clinical data and available so that patients can be managed appropriately. Read More >

Pages: 12